Patent · US Active

Method of inhibiting DYRK1B

US9951050B2 · kind B2 · utility

6Cited by

1References

18Claims

0Family size

Assignee

4SC AG · DE

Inventors

Fritz Aberger · Salzburg, AT
Wolfgang Gruber · Bischofswerda, DE
Johann Leban · Planegg, DE
Hella KOHLHOF · Munich, DE
Daniel VITT · Germering, DE
Roland BAUMGARTNER · Birkenfeld, DE

Key dates

Filing date	Jun 18, 2014
Grant date	Apr 24, 2018
Priority date	—
Expiry date	Jul 15, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.